Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region

GBI Research, August 2012, Pages: 85

Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region

Summary

GBI Research's report, “Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region"" provides detailed insight into the Americas API market. The research presents detailed analysis and forecasts of the major economic and market trends affecting the API markets in this region. The report contains market forecasts, product type analysis, drivers and restraints. In addition, it includes market forecasts, product type analysis, therapeutic categories analysis and CMO growth in the region and its influence on API manufacturing activity towards 2017. Overall, the report presents a comprehensive analysis of the Americas API market, covering all the major parameters.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Americas is the second largest regional market for APIs by revenue in the world. Americas active pharmaceutical ingredients (API) market revenue held a share of around 42.5% of global API market revenue of 108.6 $ billion in 2011. Total revenue generated by the Americas API market was $46.1 billion in 2011 and is expected to grow at a CAGR of 5.6% to reach $63.8 billion by 2017.This will be supported by healthy demand from biotech and generic API sectors.

Scope

- Market revenue data for APIs from 2005 to 2011 and forecast for six years to 2017.

- API markets in key countries in the region: North America ,South and Central America and key countries like the US and Canada

- API industry structure and market trends such as a shift in manufacturing and growth in biotechnology for the Americas region.

- Drivers of the API market, such as the growth of generic drugs, and restraints, such as patent expiries and government initiatives like price reimbursement cut.

- Detailed historical, forecast trend and share analysis of API revenue based on product types (Synthetic and Biotech APIs) in the Americas market and in key countries of the region.

- Detailed historical, forecast trend and share analysis of API revenue based on customer base (Generic and Innovative for Synthetic APIs) (Biosimilars and biologics for Biotech Apis) in the Americas market and in key countries of the region.

- Analysis of API revenue based on therapeutic categories in the North America ,South and Central America

Reasons to buy

- Develop business strategies with the help of specific insights on the Americas API market.

- Identify opportunities and challenges in the Americas API market.

- Invest in the growing segments of the API market.

- Increase future revenue and profitability with the help of insights on the future opportunities and critical success factors in the Americas API market.

- Benchmark your operations and strategies against the major players in the global API market

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction

3 Contract Manufacturing Organizations in the Americas' API Manufacturing
3.1 Introduction
3.1.1 Steps Involved in Outsourcing API Manufacturing to Contract Manufacturing Organizations
3.1.2 The US Contract Manufacturing Organization Market

4 The Americas' Active Pharmaceutical Ingredients Market
4.1 Market Overview
4.1.1 API Classification Based on Synthesis Routes
4.1.2 Classification Dependent on Customer Base
4.2 Industry Structure
4.3 Pricing and reimbursement in Americas
4.4 The US Healthcare System - Introduction
4.4.1 Health Insurance
4.5 Brazil Healthcare System - Introduction
4.5.1 Public Insurance
4.5.2 Private Insurance
4.6 The Americas' API Market Drivers
4.6.1 Upcoming Patent Expiries are Expected to Alter the API Market Dynamics in the Americas
4.6.2 Increasing Uptake of Biologics across Different Therapeutic Areas and Government Initiatives for Biomedical Research to Boost the API Revenues
4.6.3 Mergers and Acquisitions have Increased Significantly in the American Pharmaceutical Industry
4.6.4 Growth in the Pharmaceutical Industry and Increasing Elderly Population are Driving the Growth of the Americas' API Market
4.7 The Americas' API Market Restraints
4.7.1 Economic Downturn has Restricted Investment in the Pharmaceutical Industry
4.7.2 Lack of Cheap Labor, High Costs and Saturation of the Market are Likely to Hinder New Drug Development in the Region
4.7.3 Regulatory Changes Lead to Delays in the Launch of New Drugs
4.7.4 Patent Expiries and Increased Consumption of Generics Threatens API Revenue Growth
4.7.5 Huge Deficits Provoke Cuts in Healthcare Reimbursement
4.8 API Total Revenue Analysis in the Americas
4.8.1 The Americas' Revenue Share by Product Types
4.8.2 The Americas' Synthetic API Total Synthetic Revenue Analysis (2005–2017)
4.8.3 The Americas' Synthetic API Market Revenue Share Analysis by Customer Base in 2011
4.8.4 The Americas' Synthetic API Revenue Trend Analysis 2005–2017
4.9 The Americas' Biotech API Market Analysis
4.9.1 The Americas' Biotech API Revenue Analysis 2005–2017
4.10 The Americas' Biotech API Market Revenue Analysis by Customer Base
4.10.1 The Americas' Biotech API Market Revenue Share Analysis by Customer Base
4.10.2 Patent Expiry of Leading Biologics in the Americas
4.10.3 The Americas' Biotech API Revenue Trend Analysis 2005–2017

5 North American Active Pharmaceutical Ingredients Market
5.1 North American API Market Overview
5.2 North American API Market Drivers
5.2.1 Continuous Growth in the Pharmaceutical Industry Sustains the API Market's Growth in North America
5.2.2 Generic Sector Spurs the Growth of the North American API Market
5.2.3 Increasing Focus on Biological Drugs Helps the API Market's Revenue Growth
5.3 North American API Market Restraints
5.3.1 Recent Economic Slowdown has Restricted the Growth of the Pharmaceutical Industry
5.3.2 High Cost of New Drug Development Hampers Innovation
5.3.3 Patent Expiries of Blockbuster Molecules will Contain the Growth of the API Market in North America
5.4 North American Total API Revenue Analysis based on Synthesis Routes 2005–2017
5.5 North American API Revenue Share Analysis by Product Types 2005–2017
5.6 North American API Revenue Analysis Dependent on Customer Base
5.6.1 North American Synthetic API Revenue Analysis by Customer Base, 2005–2017
5.6.2 North American Synthetic API Market Revenue Share Analysis by Customer Base, 2005–2017
5.6.3 North American Biotech API Revenue Analysis by Customer Base, 2005–2017
5.6.4 North American Biotech API Revenue Share Analysis by Customer Base, 2005–2017
5.7 North American API Revenue Share Analysis by Therapeutic Applications

6 The US Active Pharmaceutical Ingredients Market
6.1 The US API Market Overview
6.2 The US Total API Revenue Analysis Based on Synthesis Routes 2005–2017
6.3 The US API Revenue Share Analysis by Product Types 2005–2017
6.4 The US API Revenue Analysis Dependent on Customer Base
6.4.1 The US Synthetic API Revenue Analysis by Customer Base, 2005–2017
6.4.2 The US Synthetic API Market Revenue Share Analysis by Customer Base, 2005–2017
6.4.3 The US Biotech API Revenue Analysis by Customer Base, 2005–2017
6.4.4 The US Biotech API Revenue Share Analysis by Customer Base, 2005–2017

7 Canadian Active Pharmaceutical Ingredients Market
7.1 Canadian API Market Overview
7.2 Canadian Total API Revenue Analysis based on Synthesis Routes 2005–2017
7.3 Canadian API Revenue Share Analysis by Product Types 2005–2017
7.4 Canadian API Revenue Analysis Dependent on Customer Base
7.4.1 Canadian Synthetic API Revenue Analysis by Customer Base, 2005–2017
7.4.2 Canadian Synthetic API Market Revenue Share Analysis by Customer Base, 2005–2017
7.4.3 Canadian Biotech API Revenue Analysis by Customer Base, 2005–2017
7.4.4 Canadian Biotech API Revenue Share Analysis by Customer Base, 2005–2017

8 South and Central America Active Pharmaceutical Ingredients Market
8.1 South and Central American API Market Overview
8.2 South and Central America API Market Drivers
8.2.1 Government Initiatives and Growing Investments in the Pharmaceutical Industry Gives a Boost to API Market Growth
8.2.2 Improvement in Regulatory Environment
8.2.3 Increasing Number of Clinical Trials Leading to Market Growth
8.2.4 Ageing Population and Increasing Prevalence of Lifestyle Diseases Fuel Market Growth
8.3 South and Central American API Market Restraints
8.3.1 Import Dependence for APIs Restricts Market Growth
8.3.2 Delay in Regulatory Processes Hinders the Industry Growth
8.4 South and Central American Total API Revenue Analysis based on Synthesis Routes 2005–2017
8.5 South and Central American API Revenue Share Analysis by Product Types 2005–2017
8.6 South and Central American API Revenue Analysis Dependent on Customer Base
8.6.1 South and Central American Synthetic API Revenue Analysis by Customer Base, 2005–2017
8.6.2 South and Central American Synthetic API Market Revenue Share Analysis by Customer Base, 2005–2017
8.6.3 South and Central American Biotech API Revenue Analysis by Customer Base, 2005–2017
8.6.4 South and Central American Biotech API Revenue Share Analysis by Customer Base, 2005–2017
8.7 South and Central American API Revenue Share Analysis by Therapeutic Applications

9 Appendix
9.1 Abbreviations
9.2 Market Definitions
9.3 References
9.4 Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.4.4 Expert Panel Validation
9.5 Contact Us
9.6 Disclaimer

1.1 List of Tables

Table 1: CMO Market, the US, Revenue Analysis ($bn), 2005–2017
Table 2: API, the Americas, Total Revenue Analysis, $m, 2005–2017
Table 3: API, the Americas, Revenue Share by Product Types, (%) 2011
Table 4: Synthetic API, the Americas, Revenue Analysis, $bn, 2005–2017
Table 5: Synthetic API, the Americas, Revenue Share Analysis , (%) 2011
Table 6: Synthetic API, the Americas, Revenue Share Analysis by Region, %, 2005–2017
Table 7: Synthetic API, the Americas, Revenue Share by Customer Base, (%), 2011
Table 8: Synthetic API, the Americas, Revenue Analysis by Customer Base, $m, 2005–2017
Table 9: Biotech API, the Americas, Revenue Analysis, ($m), 2005–2017
Table 10: Biotech API, the Americas, Revenue Share Analysis, %, 2011
Table 11: Biotech API, the Americas, Revenue Share, %, 2005–2017
Table 12: The Americas' Biotech API Market, Revenue Share Analysis by Customer Base, 2011
Table 13: Biotech API, the Americas, Patent Expiry of Leading Biologics, 2003–2017
Table 14: Biotech API, the Americas, Revenue Analysis by Customer Base, $m, 2005–2017
Table 15: API Market, North America, Major Drugs to Lose Patent Protection, 2012 and 2016
Table 16: API, North America, Revenue Analysis by Product Types, $m, 2005–2017
Table 17: API, North America, Revenue Share by Product Type, %, 2005–2017
Table 18: Synthetic API, North America, Revenue Analysis by Customer Base, $m, 2005–2017
Table 19: Synthetic API, North America, Revenue Share by Customer Base, %, 2005–2017
Table 20: Biotech API, North America, Revenue Analysis by Customer Base, $m, 2005–2017
Table 21: Biotech API, North America, Revenue Share by Customer Base, %, 2005–2017
Table 22: API, North America, Revenue Split by Therapeutic Applications, %, 2011–2017
Table 23: API, the US, Revenue Analysis by Product Types, $m, 2005–2017
Table 24: API, the US, Revenue Share by Product Type, %, 2005–2017
Table 25: Synthetic API, the US, Revenue Analysis by Customer Base, $m, 2005–2017
Table 26: Synthetic API, the US, Revenue Share by Customer Base, %, 2005–2017
Table 27: Biotech API, the US, Revenue Analysis by Customer Base, $m, 2005–2017
Table 28: Biotech API, the US, Revenue Share by Customer Base, %, 2005–2017
Table 29: API, Canada, Revenue Analysis by Product Types, $m, 2005–2017
Table 30: API, Canada, Revenue Share by Product Type, %, 2005–2017
Table 31: Synthetic API, Canada, Revenue Analysis by Customer Base, $m, 2005–2017
Table 32: Synthetic API, Canada, Revenue Share by Customer Base, %, 2005–2017
Table 33: Biotech API, Canada, Revenue Analysis by Customer Base, $m, 2005–2017
Table 34: Biotech API, Canada, Revenue Share by Customer Base, %, 2005–2017
Table 35: API, South and Central America, Revenue Analysis by Product Types, $m, 2005–2017
Table 36: API, South and Central America, Revenue Share by Product Type, %, 2005–2017
Table 37: Synthetic API, South and Central America, Revenue Analysis by Customer Base, $m, 2005–2017
Table 38: Synthetic API, South and Central America, Revenue Share by Customer Base, %, 2005–2017
Table 39: Biotech API, South and Central America, Revenue Analysis by Customer Base, $m, 2005–2017
Table 40: Biotech API, South and Central America, Revenue Share by Customer Base, %, 2005–2017
Table 41: API, South and Central America, Revenue Split by Therapeutic Applications, %, 2011–2017

1.2 List of Figures

Figure 1: CMO Market, the US, Revenue Analysis ($bn), 2005–2017
Figure 2: The Americas' API Market, Product Types
Figure 3: API, the Americas, Value Chain, 2011
Figure 4: API, the Americas, Total Revenue Analysis, $m, 2005–2017
Figure 5: API, the Americas, Revenue Share by Product Types, (%), 2011
Figure 6: Synthetic API, the Americas, Revenue Analysis, ($m), 2005–2017
Figure 7: Synthetic API, the Americas, Revenue Share Analysis , (%), 2011
Figure 8: Synthetic API, the Americas, Revenue Share Analysis by Region, (%), 2005–2017
Figure 9: Synthetic API, the Americas, Revenue Share by Customer Base, (%), 2011
Figure 10: Synthetic API, the Americas, Revenue Analysis by Product Types, ($m), 2011
Figure 11: Biotech API, the Americas, Revenue Analysis,($m), 2005–2017
Figure 12: Biotech API, the Americas, Revenue Share Analysis, (%), 2011
Figure 13: Biotech API, the Americas, Revenue Share, (%), 2005–2017
Figure 14: Biotech API, the Americas, Revenue Share Analysis by Customer Base, (%), 2011
Figure 15: Biotech API, the Americas, Revenue Analysis by Customer Base, ($m) Types, 2005–2017
Figure 16: API, North America, Revenue Analysis by Product Types, ($m), 2005–2017
Figure 17: API, North America, Revenue Share by Product Type, (%), 2005–2017
Figure 18: Synthetic API, North America, Revenue Analysis by Customer Base, ($m), 2005–2017
Figure 19: Synthetic API, North America, Revenue Share by Customer Base, (%), 2005–2017
Figure 20: Biotech API, North America, Revenue Analysis by Customer Base, ($m), 2005–2017
Figure 21: Biotech API, North America, Revenue Share by Customer Base, (%), 2005–2017
Figure 22: API, North America, Revenue Split by Therapeutic Applications, (%), 2011–2017
Figure 23: API, the US, Revenue Analysis by Product Types, ($m), 2005–2017
Figure 24: API, the US, Revenue Share by Product Type, (%), 2005–2017
Figure 25: Synthetic API, the US, Revenue Analysis by Customer Base, ($m), 2005–2017
Figure 26: Synthetic API, the US, Revenue Share by Customer Base, (%), 2005–2017
Figure 27: Biotech API, The US, Revenue Analysis by Customer Base, ($m), 2005–2017
Figure 28: Biotech API, The US, Revenue Share by Customer Base, (%), 2005–2017
Figure 29: API, Canada, Revenue Analysis by Product Types, ($m), 2005–2017
Figure 30: API, Canada, Revenue Share by Product Type, (%), 2005–2017
Figure 31: Synthetic API, Canada, Revenue Analysis by Customer Base, ($m), 2005–2017
Figure 32: Synthetic API, Canada, Revenue Share by Customer Base, (%), 2005–2017
Figure 33: Biotech API, Canada, Revenue Analysis by Customer Base, ($m), 2005–2017
Figure 34: Biotech API, Canada, Revenue Share by Customer Base, (%), 2005–2017
Figure 35: API, South and Central America, Revenue Analysis by Product Types, ($m), 2005–2017
Figure 36: API, South and Central America, Revenue Share by Product Type, (%), 2005–2017
Figure 37: Synthetic API, South and Central America, Revenue Analysis by Customer Base, ($m), 2005–2017
Figure 38: Synthetic API, South and Central America, Revenue Share by Customer Base, (%), 2005–2017
Figure 39: Biotech API, South and Central America, Revenue Analysis by Customer Base, ($m), 2005–2017
Figure 40: Biotech API, South and Central America, Revenue Share by Customer Base, (%), 2005–2017
Figure 41: API, South and Central America, Revenue Split by Therapeutic Applications, (%), 2011–2017

South and Central America Active Pharmaceutical Ingredients Market Closing Gap on Northern Neighbors

The active pharmaceutical ingredients (API) market in the Americas was worth a staggering $46 billion in 2011, with North America accounting for over 88% of it. But thanks to rapidly expanding economies and improvements in healthcare, South and Central America (SCA) are set to take a more substantial chunk in the future, predicts pharmaceutical industry analysts GBI Research in their latest report.

According to the report*, the SCA region has one of the fastest growing API markets in the world, with a growing demand for generic and biologic medications. Mexico is currently the largest market in the region, but thanks to an aging population and a strengthening healthcare system, Brazil is expected to overtake by 2017.

SCA countries are becoming increasingly open to global drug producers and supporting the manufacture of medications at home through investments. Many governments in the region are aware of the huge potential of generics and are providing financial backing as well as promoting pharmaceutical growth through the employment of various programs and schemes.

This region is also home to an expanding aging population and is witnessing an increase in lifestyle diseases such as diabetes and obesity – further driving the demand for healthcare and pharmaceutical treatments.

The API market in South and Central America was valued at $5.4 billion in 2011 and is expected to climb at a Compound Annual Growth Rate (CAGR) of nearly 13% to reach 11.1 billion in 2017. As the North American API market is expected to grow at a more modest CAGR of 4.4%, the SCA will increase its share of the total Americas market to 17.4% from the 11.7% stake held in 2011.

*Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region

This research presents detailed analysis and forecasts of the major economic and market trends affecting the API markets in this region.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Medical Nutrition - A Global Market Overview
• Diabetes Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Syringes (Disposable and Reusable) - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• Dental Supplies - Global Strategic Business Report
• Anesthesia Disposables - Global Strategic Business Report
• Clinical Diagnostics Automation - Global Business Strategic Report
• Ostomy and Incontinence Products - Global Strategic Business Report